Here is the short answer people rarely hear plainly: the dosing does not change. Mounjaro and Zepbound are both tirzepatide, made by the same manufacturer, and they use the identical dose ladder from 2.5 mg to 15 mg once weekly. What actually changes between them is the approved use on the label, which condition insurers will pay for, and how you get a prescription. The milligrams are the same. The paperwork around them is not.
That distinction matters because a lot of confusion in the mounjaro vs zepbound question comes from assuming two brand names mean two formulas. They do not. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and, separately, for moderate to severe obstructive sleep apnea in adults with obesity. Same drug, two doors.
What is the actual dose ladder?
Both products follow the same titration on their labels. Treatment starts at 2.5 mg injected once weekly for four weeks. That first dose is not meant to do much clinically. It exists to let the gut adjust and blunt the nausea, and the vomiting that can come with a new GIP and GLP-1 receptor agonist. After four weeks the dose steps to 5 mg. From there, if more effect is needed and the current dose is tolerated, a prescriber can move up to 7.5 mg, then 10, 12.5, and 15 mg, with at least four weeks between increases.
The prescribing information for each brand lays this out in the same terms. Anyone who wants to check the exact language can read the MOUNJARO prescribing information and the ZEPBOUND prescribing information side by side. The titration tables read almost identically because the underlying medicine is identical.
Why do the pens look different?
The delivery devices and packaging carry different brand identities, and Zepbound has been sold in single-dose vials as well as pens in the United States, partly to widen access during supply strain. That is a format difference, not a strength difference. A 10 mg Zepbound vial and a 10 mg Mounjaro pen deliver the same amount of tirzepatide. The choice between them tends to come down to what a plan covers and what a pharmacy has in stock, not to any dosing advantage.
Does the target condition change how it is dosed?
In practice, less than people expect. The starting point and the maximum are the same for diabetes and for weight management. What differs is the goal that guides how far up the ladder a prescriber climbs. For type 2 diabetes, the target is blood sugar control, so a dose that brings A1c to goal may be the stopping point even if it is not the maximum. For weight management, clinicians often titrate toward the highest tolerated dose because the key obesity trial showed dose-related results.
That trial, SURMOUNT-1, reported average weight reductions of roughly 15 percent at 5 mg and about 21 percent at 15 mg over 72 weeks. The findings are summarized in the report on tirzepatide once weekly for the treatment of obesity. A separate study in Chinese adults, SURMOUNT-CN, found similar dose-related benefit in a different population. Neither result means everyone should push to 15 mg. It means the ceiling exists for people who need it and tolerate it.
How do the two compare on the practical points?
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide |
| Approved use | Type 2 diabetes | Chronic weight management, obstructive sleep apnea with obesity |
| Dose ladder | 2.5 to 15 mg weekly | 2.5 to 15 mg weekly |
| Titration interval | At least 4 weeks per step | At least 4 weeks per step |
| Coverage logic | Diabetes benefit | Weight or sleep apnea benefit |
What happens when you switch or maintain?
Because strengths and schedule match, a person moving from Mounjaro to Zepbound, or the reverse, can usually stay at the same weekly dose. Prescribers do this often when a coverage situation changes, for instance when a diabetes plan stops covering the drug and a weight indication opens a different route. The switch is administrative rather than a fresh titration, assuming the current dose is being tolerated.
Staying on the drug matters more than most dose debates. The SURMOUNT-4 maintenance trial found that people who stopped tirzepatide regained a large share of lost weight, while those who continued kept losing or held steady. That is worth weighing before treating the drug as a short course. The dose you can sustain over time is the dose that counts.
How does tirzepatide stack up against other options?
A head-to-head comparison published in 2024 looked at semaglutide versus tirzepatide for weight loss and reported greater average reduction with tirzepatide, detailed in the report on semaglutide versus tirzepatide for weight loss in adults with overweight or obesity. The dual mechanism is part of the story, and the pharmacology of GLP-1 and dual GIP and GLP-1 agonists is reviewed in a 2024 paper on mechanisms of action and therapeutic applications. Newer oral agents are also arriving; orforglipron, an oral small-molecule GLP-1 agonist, was approved for weight management in 2026 and its trial data appear in the report on orforglipron for obesity treatment.
Where do access and compounded options fit?
Both brands can be hard to afford and, at times, hard to find. That gap pushed many people toward compounded tirzepatide, which is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same molecule, but it has not passed through the approval process that produced the brand trial evidence, and no one should self-set a dose from a vial with no approved product behind it. Physician-supervised telehealth services, among them Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare, sit across the range from brand fulfillment to supervised compounded care, and for readers weighing a compounded route one such practice publishes the full details here with prescribing handled by a licensed clinician. The dosing decision still belongs with that clinician, not with a price page.
Key takeaways
- Mounjaro and Zepbound are the same molecule, tirzepatide, with the same 2.5 to 15 mg weekly ladder.
- The real difference is approved use and coverage: diabetes for one, weight and sleep apnea for the other.
- The 2.5 mg dose is a starting step to reduce side effects, not a treatment dose.
- The highest tolerated dose that works is the goal, not the maximum number on the label.
- Compounded tirzepatide is not FDA-approved and its dose must come from a prescriber.
See also: The Copper Peptide That Got Famous Before It Got Studied
Frequently asked questions
Are Mounjaro and Zepbound the same drug?
Both contain tirzepatide, the same dual GIP and GLP-1 receptor agonist made by the same manufacturer. They share an identical dose ladder from 2.5 mg to 15 mg. The difference is the approved use printed on the label, not the active molecule.
Does the dose ladder differ between the two?
No. Both start at 2.5 mg once weekly for four weeks, then step up to 5 mg, and can move to 7.5, 10, 12.5, and 15 mg at intervals of at least four weeks. The 2.5 mg dose is a starting dose meant to reduce stomach side effects, not a treatment dose.
Can I switch from one to the other at the same dose?
Because the milligram strengths and schedule match, a prescriber can usually continue the same weekly dose across the two. The change is administrative, tied to indication and coverage, rather than a change in the medication itself.
Is a higher dose always better for weight loss?
Not necessarily. Trials showed dose-related benefit, but the highest tolerated dose that produces steady results is the goal, not the maximum number. Some people do well at 5 mg or 10 mg and never need 15 mg.
Is compounded tirzepatide the same as either brand?
No. Compounded tirzepatide is prepared by a pharmacy and is not an FDA-approved product. It may contain the same molecule, but it has not gone through the approval process behind the brand trial evidence, and its dosing should be set by a prescriber.
